YKST 03
Alternative Names: anti-CD3×TROP2 bispecific antibody; TROP2-CD3 bispecific antibody; YKST-03Latest Information Update: 09 Oct 2024
Price :
$50 *
At a glance
- Originator Excyte Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 04 Oct 2024 Preclinical trials in Triple-negative-breast-cancer in China (Parenteral) prior to October 2024 (Excyte Biopharma pipeline, October 2024)
- 04 Oct 2024 Excyte Biopharma plans to file an IND application in China for Triple negative breast cancer in October 2024 (Excyte Biopharma pipeline, October 2024)